Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium lactis UABLA-12
- Development stage
- Unknown
- Lead developer
- UAS Labs
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium lactis UABLA-12 is a proprietary probiotic strain of Bifidobacterium animalis subsp. lactis, used as a dietary supplement to support gastrointestinal health and immune function. It has been studied in randomized controlled trials for its efficacy in improving symptoms of irritable bowel syndrome (IBS), including abdominal pain, symptom severity, and normalization of bowel habits[1][3][6]. Mechanistically, this probiotic acts by modulating the gut microbiota, enhancing barrier function in the gut mucosa, inhibiting pathogens through acid production and competitive exclusion, and supporting immune regulation[4][5]. Supplementation with B. lactis UABLA-12 has also been associated with improved stool consistency and potential benefits for lactose digestion and micronutrient synthesis[5].
- Brand names
- UABla-12UABla12UABla 12
- Other names
- bifidobacterium animalis subsp. lactis UABla-12B. lactis UABla-12
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on bifidobacterium lactis UABLA-12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium lactis UABLA-12.